Biopharma companies are rapidly evolving the way they integrate data and processes within clinical, regulatory, safety and quality functions.
In 2026, the focus will be on creating seamless, connected execution between teams, supported by a robust technology infrastructure.
This will enhance data transparency, traceability and inspection readiness, particularly as European regulatory expectations continue to change. Simultaneously, artificial intelligence will transition from early stage capability augmentation to serving as a practical tool that operates within well-defined boundaries.
Rik van Mol, Senior Vice President, R&D and Quality at Veeva Systems, offers four predictions for 2026 in the life sciences sector.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.